Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial
A general small-to-moderate magnitude decline in cognition occurred with zuranolone alone. Coadministration with alprazolam/ethanol increased the magnitude, but not the duration, of effects compared with single-agent administration. Zuranolone prescribers and patients should be aware of the potential for increased central nervous system-depressant effects if coadministered with GABAergic active compounds such as alprazolam and ethanol.
Authors
- Indrani Nandy
- Seth Levin (ORCID: https://orcid.org/0000-0001-9222-1094)
- Andrew H. Czysz (ORCID: https://orcid.org/0000-0002-0832-1760)
- David P. Walling (ORCID: https://orcid.org/0000-0001-8638-2086)
- Victor Ona
- Paul Maruff (ORCID: https://orcid.org/0000-0002-6947-9537)
- Joi Dunbar (ORCID: https://orcid.org/0009-0004-7663-1535)
- Rakesh K. Jain
- Margaret K Moseley
- Howard A Hassman
Institutions
- Texas Tech University (US)
- Biogen (United States) (US)
- Connecticut Sea Grant (US)
- Hassman Research Institute (US)
- Sage Therapeutics (United States) (US)
Publication Details
- Journal
- Journal of Psychopharmacology
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1177/02698811241282777
- Citations
- 3
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 1.34
Funders
- Biogen
- Sage Therapeutics